Skip to content
Artos logo

Artos

Hiring

Artos is a YC Winter 2024 (W24) company. Team of 6.

About Artos

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Artos builds an AI-powered document drafting and management platform for biopharma companies preparing regulatory submissions. It takes raw clinical and non-clinical data and generates the full CTD pyramid of documents, including INDs, NDAs, and BLAs, that regulators require before a drug or biologic can be sold. This replaces a manual writing process that typically consumes months of work by medical writers and regulatory affairs teams.

Go-to-market

Biopharma regulatory and medical writing teams are the buyers, reached through a sales-led, demo-request motion as shown on the website.

From the Y Combinator listing

How Artos describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Authoring documents for life sciences in minutes, not months.

Artos is an AI-based document-drafting platform that helps life sciences companies turn their data into critical documents in minutes. These submissions currently take months and are the final hurdle before life sciences companies are allowed to sell their product.

Facts

Industry
B2B / B2B
Team size
6
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works